A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children’s Hospital of Philadelphia (CHOP).
In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups are seen as rife with fresher thinking — companies where